-
ASHP: What pharmacy leaders should know heading into 2024
More than three-fourths of hospital pharmacy leaders think health systems will cut service lines because of the rising cost and complexity of new drugs, according to a report released Dec. 4. -
Former Allied Health pharmacy transfers to WVU Hospitals ownership
Morgantown, W.Va.-based WVU Medicine will operate a specialty pharmacy that is currently operated by Allied Health Services, WVU Medicine's for-profit organization. -
AbbVie eyes commercial ovarian cancer market with ImmunoGen deal
Pharmaceutical giant AbbVie announced plans to acquire antibody-drug conjugate maker ImmunoGen to expand its oncology portfolio and enter the commercial market for ovarian cancer. -
Pfizer cancels weight loss drug candidate
Pfizer's weight loss drug candidate, danuglipron, helped patients shed between 4.8% and 13% body weight in a clinical trial involving patients with and without obesity, but the drugmaker is canceling research after more than half stopped taking the drug. -
Walgreens launches prescription pricing tool
Walgreens rolled out its new Rx Savings Finder on Nov. 30, a free tool offering discount cards for thousands of medications. -
3 drugs nearing approval to know: Optum
Optum Rx, a subsidiary of UnitedHealth Group, is keeping close tabs on three drug candidates that might be approved in the next few months, according to its fall 2023 report. -
FDA again warns drug facility where workers poured acid on quality data
The FDA sent another warning to an Intas Pharmaceuticals plant in India, where investigators imposed import bans in late 2022 after finding shredded quality control documents doused in acid. -
Only device for Janssen pulmonary hypertension drug discontinued
Janssen is recommending physicians withhold prescribing its pulmonary arterial hypertension drug because Philips Respironics is discontinuing the only approved delivery system for the drug. -
Mark Cuban drug company taps mail-order pharmacy
Mark Cuban Cost Plus Drug Co. is teaming up with PharmcoRx, a pharmacy services business, to expand its pharmacy affiliate network. -
Reading Hospital to open 3rd pharmacy
West Reading, Pa.-based Reading Hospital is planning to open a full-service retail pharmacy Nov. 29 in Wyomissing, Pa., according to Lehigh Valley Business. -
Some antiseizure drugs can cause extensive rash, FDA warns
Antiseizure medications made of levetiracetam and clobazam might cause a rash that can quickly injure organs and hospitalize patients, the FDA said Nov. 28. -
Menopausal women turn to Wegovy, Ozempic for weight loss
A popular class of Type 2 diabetes and weight management drugs is gaining the attention of women going through menopause who want to lose weight, The New York Times reported Nov. 27. -
FDA approves 1st drug for aggressive, noncancerous tumors
The FDA approved Ogsiveo (nirogacestat), the first drug indicated for locally aggressive, noncancerous tumors, on Nov. 27. -
Cost Plus Drugs partners with digital health company
Mark Cuban Cost Plus Drug Co. has partnered with digital health company Expion Health in an effort to tackle the rising costs of specialty drugs. -
MercyOne hospital scoops pharmacy
Genesis Medical Center-Dewitt, a MercyOne-owned hospital in Iowa, bought a local pharmacy to include in its network, Our Quad Cities reported Nov. 27. -
Mounjaro more effective than Ozempic for weight loss: Study
Eli Lilly's Mounjaro helped patients lose weight more effectively than Novo Nordisk's Ozempic, according to a preprint study that included more than 40,000 patients. -
Exela Pharma recalls 400K drugs
Exela Pharma Sciences, an injectable drug company, is recalling more than 415,000 drug vials in a Class I recall because of a possible presence of silicone, according to the FDA. -
Uptake of RSV drugs spikes early
The fill rate of antibiotics for bacterial infections from respiratory syncytial virus surpassed the previous season's trend, indicating an unusually early RSV season. -
Surgeons raise concerns about Ozempic, other GLP-1s
Surgeons and health system leaders are voicing concerns about the unknown long-term risks of glucagon-like peptide-1 receptor agonists, such as Ozempic, Wegovy and Saxenda. -
FDA finalizes tougher rules for consumer drug ads
The FDA issued a final rule Nov. 21 that will require drugmakers to clearly state side effects and contraindications in direct-to-consumer advertisements. The rule is effective May 20, 2024.
Page 24 of 50